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Clinical PerspectiveWhat Is New?Persistently elevated cardiovascular disorder--related risk across all severity forms of congenital heart defects (CHD) suggests that postoperative cardiovascular sequelae continue to impose a significant burden despite improvements in the surgical management of CHD.Excess mortality from non‐CHD/noncardiovascular disorder causes remains unchanged over time, suggesting limited progress in the management or prevention of these additional non‐CHD morbidities.What Are the Clinical Implications?Myocardial protection during congenital heart surgery, emergence of new medications, provision of implantable defibrillators to those at risk for sudden arrhythmic death, and interdisciplinary clinical investigation may all attenuate the late risks from postoperative morbidities in the population with repaired CHD.

Introduction {#jah33669-sec-0008}
============

Children undergoing congenital heart surgery (CHS) are at risk for both early and late mortality, but most prior research has focused on survival to hospital discharge. Studies of long‐term outcomes have shown elevated risk for premature mortality across all forms of congenital heart defects (CHD), and defined high‐risk groups by CHD characteristics.[1](#jah33669-bib-0001){ref-type="ref"}, [2](#jah33669-bib-0002){ref-type="ref"}, [3](#jah33669-bib-0003){ref-type="ref"}, [4](#jah33669-bib-0004){ref-type="ref"} We recently examined this excess risk for survivors of CHS in the Pediatric Cardiac Care Consortium (PCCC), a large US‐based registry for interventions for CHD[5](#jah33669-bib-0005){ref-type="ref"} and found the standardized mortality ratio (SMR) to range from 4.3 times (95% confidence interval \[CI\] 3.7--5.0) for mild diseases, to 5.8 for moderate (95% CI: 4.2--7.9), 12.4 for severe two‐ventricle (95% CI: 11.5--13.4) and 35 times (95% CI: 33--38) above the general population.[4](#jah33669-bib-0004){ref-type="ref"} Less is known, though, about the eventual causes of death (COD) among patients surviving to hospital discharge after the initial CHS or after their final corrective or palliative surgery.[1](#jah33669-bib-0001){ref-type="ref"}, [6](#jah33669-bib-0006){ref-type="ref"}, [7](#jah33669-bib-0007){ref-type="ref"}, [8](#jah33669-bib-0008){ref-type="ref"}, [9](#jah33669-bib-0009){ref-type="ref"}

Patients operated for CHD may be at risk for premature mortality related to abnormal cardiac function and arrhythmias, systemic and pulmonary vascular abnormalities, and impaired lung function.[7](#jah33669-bib-0007){ref-type="ref"}, [8](#jah33669-bib-0008){ref-type="ref"}, [9](#jah33669-bib-0009){ref-type="ref"}, [10](#jah33669-bib-0010){ref-type="ref"}, [11](#jah33669-bib-0011){ref-type="ref"}, [12](#jah33669-bib-0012){ref-type="ref"} In addition, they frequently have coexisting extracardiac abnormalities and predispositions for neurologic and cerebrovascular disorders, gastrointestinal/hepatic, renal, endocrine, and neoplastic disorders.[13](#jah33669-bib-0013){ref-type="ref"}, [14](#jah33669-bib-0014){ref-type="ref"}, [15](#jah33669-bib-0015){ref-type="ref"}, [16](#jah33669-bib-0016){ref-type="ref"}, [17](#jah33669-bib-0017){ref-type="ref"}, [18](#jah33669-bib-0018){ref-type="ref"}, [19](#jah33669-bib-0019){ref-type="ref"}, [20](#jah33669-bib-0020){ref-type="ref"} Patients with operated CHDs are also exposed to other risks such as additional interventions, diagnostic radiation,[21](#jah33669-bib-0021){ref-type="ref"}, [22](#jah33669-bib-0022){ref-type="ref"} chronic use of medications,[23](#jah33669-bib-0023){ref-type="ref"} and psycho‐emotional sequences[24](#jah33669-bib-0024){ref-type="ref"}, [25](#jah33669-bib-0025){ref-type="ref"} leading to suicidal behavior or alcoholism.[26](#jah33669-bib-0026){ref-type="ref"} Furthermore, CHD patients are concurrently exposed to the same cardiovascular and other risk factors as the general population and may react differently to conditions such as aging and pregnancy.[10](#jah33669-bib-0010){ref-type="ref"}, [18](#jah33669-bib-0018){ref-type="ref"}, [27](#jah33669-bib-0027){ref-type="ref"} These exposures may create an additive organ injury leading to increased morbidity above the general population.[28](#jah33669-bib-0028){ref-type="ref"} Consequently, CHD patients are expected to experience different COD than the general population.

We recently reported the 25‐year survival outcomes of 35 998 children undergoing CHS in the United States between 1982 and 2003 by linking the PCCC with the US National Death Index (NDI).[5](#jah33669-bib-0005){ref-type="ref"} Long‐term survival was decreased across all forms of CHD including even the mildest lesions.[4](#jah33669-bib-0004){ref-type="ref"} We now examine the COD in this cohort to evaluate differential risks that may inform targeted surveillance for specific patient groups.

Methods {#jah33669-sec-0009}
=======

We conducted a retrospective cohort study using data from the PCCC registry enriched with prospectively collected data through linkage with the NDI. The study was approved by the Institutional Review Boards of the University of Minnesota and Emory University, by the NDI, and by the state birth registries of Minnesota, Arkansas, Ohio, South Carolina, and Missouri with waiver for informed consent for patients enrolled in the PCCC up to April 15, 2003, the date stricter Health Insurance Portability and Accountability Act rules took effect. The data, analytic methods, and study materials will be made available upon request from the corresponding author to qualified individuals completing necessary training requirements as set by the Institutional Review Board of Emory University. Shared data will be free of identifiers to protect the rights and privacy of the individuals who participate in this project as required by the Health Insurance Portability and Accountability Act Privacy Rule, and any local, state, and federal laws and regulations.

PCCC Registry {#jah33669-sec-0010}
-------------

Details of the creation, activities, and function of the PCCC have been described before.[5](#jah33669-bib-0005){ref-type="ref"}, [29](#jah33669-bib-0029){ref-type="ref"} We queried the PCCC registry for patients who (1) were US residents; (2) underwent first CHS in a US PCCC center between January 1, 1982 and April 15, 2003; (3) were \<21 years of age at the time of surgery; (4) survived to discharge after the CHS; and (5) had adequate identifiers for matching with the NDI.[30](#jah33669-bib-0030){ref-type="ref"}, [31](#jah33669-bib-0031){ref-type="ref"} We excluded low‐birth‐weight infants (\<2.5 kg at the time of surgery) with isolated patent ductus arteriosus ligation and patients with known chromosomal abnormalities because of COD associated with the underlying condition.

We abstracted demographic and clinical variables including sex, age at first surgery, year of first surgery, type of surgery, and CHD diagnosis. Information about race was obtained from the PCCC, linkage to state birth records, or death records obtained from the NDI. The subset with race information available was classified as "black," "white," or "other race."

Assignment of Cardiac Diagnosis and Classification of Defects {#jah33669-sec-0011}
-------------------------------------------------------------

Each patient is assigned one primary diagnosis using a severity‐based list of CHD and the operative strategy for the first reported CHS (Data [S1](#jah33669-sup-0001){ref-type="supplementary-material"}).[31](#jah33669-bib-0031){ref-type="ref"} We grouped conditions as mild, moderate, and severe lesions. The severe category was subdivided into single‐ (1V) and two‐ventricle lesions (2V). Further subclassification of two‐ventricular conditions into 1 of 8 categories was based on anatomo‐pathophysiologic characteristics. If more than one CHD is present, patients are classified by the hierarchically most severe diagnosis. Lesions with coexistence of different pathophysiologies are classified as complex lesions to distinguish them from the plain forms of the primary CHD lesion.[31](#jah33669-bib-0031){ref-type="ref"}

Death Ascertainment and Causes of Death Classification {#jah33669-sec-0012}
------------------------------------------------------

Death was ascertained from the PCCC and by matching to NDI records through December 31, 2014.[30](#jah33669-bib-0030){ref-type="ref"}, [31](#jah33669-bib-0031){ref-type="ref"} COD were provided by the NDI *Plus,* both as underlying and multiple or contributing COD (Data [S1](#jah33669-sup-0001){ref-type="supplementary-material"}).[32](#jah33669-bib-0032){ref-type="ref"} All COD are given as *International Classification of Disease* (*ICD*) codes.[33](#jah33669-bib-0033){ref-type="ref"} Between 1982 to 1988, the NDI used the *ICD‐9* revision, but beginning in 1999, the *ICD‐10* revision is used. Because the PCCC includes data from both ICD revisions, all *ICD‐10* codes were recoded to *ICD‐9* for tabulation purposes.

Underlying COD were grouped in the following major ICD categories: (1) congenital heart disease (CHD); (2) diseases of the circulatory system (other than CHD) (termed herein cardiovascular disorders or CVD); (3) congenital malformations; (4) diseases of the respiratory system; (5) external causes of injury and poisoning; (6) infectious diseases; (7) neoplasms; and (8) other, where all other medical causes were lumped together. COD were compared across sexes and different age‐strata (selected to match the Centers for Disease Control and Prevention reports of annual mortality), and to the general US population (Table [S1](#jah33669-sup-0001){ref-type="supplementary-material"}).

Deaths by multiple COD were classified: (1) as CHD‐associated death, when there is at least 1 ICD code related to CHD; (2) as CVD‐associated death, when there is no ICD code related to CHD but at least 1 code related to CVD; or (3) as non‐CHD/non‐CVD death when there are no codes related to CHD or CVD.

US Mortality Data {#jah33669-sec-0013}
-----------------

Mortality data for the US population for the years 1982 to 2014 were downloaded from the CDC "Wonder" website and comprise age‐, sex‐, and year‐specific death rates per 100 000 people.[34](#jah33669-bib-0034){ref-type="ref"}

Statistical Analysis {#jah33669-sec-0014}
--------------------

Underlying COD classification was compared across sexes within age‐group strata using χ^2^ tests. Time of death from first surgery was categorized (\<90 days, 90--365 days, 1--4 years, 5--9 years, 10--14 years, and \>15 years) and treated as an ordinal variable to understand trends in cause‐specific mortality. Associations between underlying COD and time from surgery were examined using a Cochran‐Armitage test for trend.

SMRs were used to quantify the cause‐specific rate of mortality in this CHD population compared with an age‐, sex‐, and calendar‐year‐matched US population (for additional information see Data [S1](#jah33669-sup-0001){ref-type="supplementary-material"}).[31](#jah33669-bib-0031){ref-type="ref"} Multivariable logistic regression was used to assess the association between race or sex and a specific COD. Models contained the overall effect of race or sex and other potential confounders: year of death, age at death, severity of CHD, sex, and race, as applicable.

All analyses were performed in SAS version 9.4 (SAS Institute Inc, Cary, NC) and an interactive figure was created using *plotly*.[35](#jah33669-bib-0035){ref-type="ref"} Statistical significance was assessed at the 0.05 level unless otherwise noted.

Results {#jah33669-sec-0015}
=======

Characteristics of Study Population {#jah33669-sec-0016}
-----------------------------------

Among the 35 998 patients who met inclusion criteria, we excluded 4866 (13.5%) patients with a known chromosomal abnormality. Patients excluded because of chromosomal anomalies tended to be younger at their first surgery, were more likely to be female, and have two‐ventricle lesions with L‐R physiology. The final cohort consisted of 31 132 patients, from 47 centers, discharged alive following their initial CHS.

A total of 2527 deaths (8.1%) occurred following discharge after the first CHS over a median follow‐up period of 18.1 years (interquartile range: 14.5--22.2). Among the deaths, 1030 (40.8%) were female and 1497 were male (59.2%). Infants (\<1 year of age) accounted for the largest share of deaths (n=994, 39.3%) followed by children aged 1 to 4 years (n=633, 25.0%). Median age at death was 1.8 years (interquartile range: 0.5--12.8). The median age of the cohort at the end of the study period was 20.9 years (interquartile range: 16.3--26.3) (Table [1](#jah33669-tbl-0001){ref-type="table"}).

###### 

Summary of Patient Characteristics in the PCCC Cohort

                                     Overall (N=31 132)   Died (N=2527)
  ---------------------------------- -------------------- -------------------
  Median age at surgery (y) (IQR)    0.96 (0.17--4.22)    0.16 (0.02--1.03)
  Sex                                                     
  Females                            14 695 (47.2%)       1030 (40.8%)
  Males                              16 437 (52.8%)       1497 (59.2%)
  Race                                                    
  White                              9421 (80.6%)         1885 (76.5%)
  Black                              1948 (16.7%)         500 (20.3%)
  Other                              327 (2.8%)           79 (3.2%)
  Missing                            19 439               63
  Physiology                                              
  Two‐ventricle lesions                                   
  L‐R Shunt                          12 361 (39.7%)       419 (16.6%)
  ASD                                5565 (17.9%)         134 (5.3%)
  PDA                                2784 (9.0%)          79 (3.1%)
  VSD (simple)                       3496 (11.2%)         126 (5.0%)
  CCAVC (simple)                     515 (1.7%)           80 (3.2%)
  LHOL                               5286 (17.0%)         331 (13.1%)
  Cor‐Tri                            74 (0.2%)            3 (0.1%)
  MS                                 69 (1.3%)            14 (0.6%)
  AS/Sub‐AS                          1263 (4.1%)          88 (3.5%)
  CoA                                3668 (11.8%)         191 (7.6%)
  IAA                                212 (0.7%)           35 (1.4%)
  APVR                               1436 (4.6%)          65 (2.6%)
  TAPVR                              672 (2.2%)           50 (2.0%)
  PAPVR                              764 (2.5%)           15 (0.6%)
  RVOTO                              3596 (11.6%)         242 (9.6%)
  PS/Sub‐PS                          697 (2.2%)           33 (1.3%)
  PA/IVS                             198 (0.6%)           22 (0.9%)
  TOF                                2701 (8.7%)          187 (7.4%)
  TGA physiology (d‐TGA simple)      1545 (5.0%)          113 (4.5%)
  Complete mixing (TAC)              204 (0.7%)           48 (1.9%)
  Complex lesions                    2510 (8.1%)          345 (13.7%)
  Complex CAVC                       44 (0.1%)            23 (0.9%)
  Complex d‐TGA                      228 (0.7%)           72 (2.9%)
  Complex VSD                        1620 (5.2%)          77 (3.1%)
  Complex TOF                        618 (2.0%)           173 (6.9%)
  Miscellaneous                      1846 (5.9%)          178 (7.0%)
  l‐TGA (2V)                         200 (0.6%)           48 (1.9%)
  MR/AI                              388 (1.3%)           40 (1.6%)
  TVA                                158 (0.5%)           28 (1.1%)
  Other                              1100 (3.5%)          62 (2.5%)
  SV                                 2348 (7.5%)          786 (31.1%)
  Left heart                         988 (3.2%)           250 (9.9%)
  Right heart                        806 (2.6%)           352 (13.9%)
  Other                              554 (1.8%)           184 (7.3%)
  Severity (two‐ventricle lesions)                        
  Mild                               10 974 (35.3%)       307 (12.2%)
  Moderate                           10 833 (34.8%)       584 (23.1%)
  Severe 2V                          4252 (13.7%)         593 (23.5%)
  N/A                                2725 (8.8%)          257 (10.2%)
  Era                                                     
  Early (1982--1992)                 9057 (29.1%)         1063 (42.1%)
  Mid (1993--1997)                   10 356 (33.3%)       788 (31.2%)
  Late (1998--2003)                  11 719 (37.6%)       676 (26.8%)

Numbers in parentheses express % unless otherwise specified. 2V indicates 2 ventricles; APVR, abnormal pulmonary venous return; AS/Sub‐AS, aortic stenosis/subaortic stenosis; ASD, atrial‐septal defect; CCAVC, complete common atrioventricular canal; CoA, coarctation of the aorta; Cor‐Tri, cor‐triatriatum; IAA, interrupted aortic arch; IQR, interquartile range; LHOL, left heart obstructive lesions; L‐R Shunt, left‐to‐right shunt lesions; MR/AI, mitral regurgitation/aortic insufficiency; MS, mitral stenosis; N/A, not classifiable; PA/IVS, pulmonary atresia with intact ventricular septum; PAPVR, partial APVR; PCCC, Pediatric Cardiac Care Consortium; PDA, patent ductus arteriosus; PS/Sub‐PS, pulmonary stenosis/subpulmonary stenosis; RVOTO, right ventricular outflow tract obstruction; SV, single ventricle; TAC, truncus arteriosus communis; TAPVR, total APVR; TGA, transposition of the great arteries; TOF, tetralogy of Fallot; TVA, tricuspid valve anomaly; VSD, ventricular septal defect.

Underlying COD {#jah33669-sec-0017}
--------------

The underlying COD was CHD in 58.8% of deaths, with most of these (79.5%) occurring before 5 years of age. Other frequent COD included cardiovascular disorders (CVD) (11.1%), and external causes of injury (8.2%) (Figure [1](#jah33669-fig-0001){ref-type="fig"}) followed by coexisting noncardiac congenital anomalies (4.7%), respiratory diseases (3.6%), infections (3.4%), and neoplasms (2.1%). All other conditions were less frequent and accounted for the remaining 8.2% of deaths combined (Table [S2](#jah33669-sup-0001){ref-type="supplementary-material"}).

![Underlying cause of death in patients undergoing congenital heart surgery. CHD indicates congenital heart defects; CVD, cardiovascular disorders.](JAH3-7-e010624-g001){#jah33669-fig-0001}

CHD/CVD was the leading underlying COD in all patients up to 34 years of age; however, the relative percentage of deaths caused by CHD declined for both sexes as patients aged, while all other causes became more common after 20 years of age (Figure [2](#jah33669-fig-0002){ref-type="fig"} and Table [S3](#jah33669-sup-0001){ref-type="supplementary-material"}). Landmark analysis based on time after the first CHS revealed a similar trend with significant drop of the percentage of deaths caused by CHD at the 90‐day, 1‐year, and 5‐year mark followed by a slower rate of decline thereafter (Table [S4](#jah33669-sup-0001){ref-type="supplementary-material"}). An almost reverse trend with increased percentage of deaths caused by CVD, neoplasms, and external causes was noted with longer follow‐up time post initial CHS. There is also a milder trend towards higher incidence of fatal respiratory conditions over time, while the percentage of deaths from associated malformations and infections remained relatively constant over the follow‐up period.

![Underlying cause of death by age and sex (Female: **A**, Male: **B**). CHD indicates congenital heart defects; CVD, cardiovascular disorders.](JAH3-7-e010624-g002){#jah33669-fig-0002}

Contributing COD {#jah33669-sec-0018}
----------------

Overall, when examining contributing COD, over two thirds of deaths (n=1722, 68.1%) had at least 1 ICD code defining CHD as the underlying or multiple COD (Figure [3](#jah33669-fig-0003){ref-type="fig"}A, [3](#jah33669-fig-0003){ref-type="fig"}B, and Table [S5](#jah33669-sup-0001){ref-type="supplementary-material"}). CVD was listed as multiple COD in over half of all CHD‐related deaths (54.1%) but only in 29.5% of the non‐CHD/non‐CVD deaths. The most frequent CVD listings were cardiac arrest (16.8%), heart failure (14.8%), and arrhythmias/conduction abnormalities (9.1%). Comparing frequency of multiple COD in patients over age 5 years (relative to those younger) revealed a relative decrease in cardiac arrest of 22.0% and heart failure by 19.5%, but an increase in arrhythmias by 38.8% and pulmonary heart disease by 13.8% (Table [S6](#jah33669-sup-0001){ref-type="supplementary-material"}). Deaths coded as unrelated to CHD or CVD (Figure [3](#jah33669-fig-0003){ref-type="fig"}A and Table [S7](#jah33669-sup-0001){ref-type="supplementary-material"}) were identified in 424 patients (6.8%). Most of these deaths were attributed to external causes but a significant number of them were attributed to coexisting malformations, respiratory diseases, and neoplasms (9%--10% each).

![**A,** Underlying or multiple causes of death by CHD severity. 1V, 1 ventricle; 2V, 2 ventricles. **B**, Underlying or multiple causes of death by CHD pathophysiology. APVR indicates abnormal pulmonary venous return; CHD, congenital heart defects; CVD, cardiovascular disorders; L‐R Shunt, left‐to‐right shunt lesions; LHOL, left heart obstructive lesions; RVOTO, right ventricular outflow tract obstruction; TAC, truncus arteriosus communis; TGA, transposition of the great arteries. Length of bars represents the relative percentage of death from a specific cause while the counts reflect the actual number of deaths in each category.](JAH3-7-e010624-g003){#jah33669-fig-0003}

Comparison to the General US Population {#jah33669-sec-0019}
---------------------------------------

Underlying COD was compared with the general US population, adjusted for age, sex, and year of death (Table [2](#jah33669-tbl-0002){ref-type="table"}). In patients with operated CHD, the risk of death caused by CHD or CVD was 67.7 times higher (95% CI: 64.5--70.8) than the general population. The separate SMRs from CHD or CVD are displayed in Table [S8](#jah33669-sup-0001){ref-type="supplementary-material"}. The overall SMR for CHD/CVD ranged from 17.6 for patients with mild CHD to 157.1 for severe two‐ventricle and 501.9 for single ventricle (SV). The increased SMR for CHD/CVD death peaked among death events between 1 and 4 years of age, but declined steadily thereafter, reaching 7.58 (95% CI: 5.63--9.53) among deaths between 25 and 34 years of age. SMRs for underlying COD by major physiology groups are presented in Table [S9](#jah33669-sup-0001){ref-type="supplementary-material"}.

###### 

Cause‐Specific SMR for Major Category Groups[a](#jah33669-note-0004){ref-type="fn"}

  Underlying Cause of Death                              Group     N       SMR (95%)        95% CI         *P* Value
  ------------------------------------------------------ --------- ------- ---------------- -------------- -----------
  CHD or CVD                                             Overall   1765    67.7             (64.5--70.8)   \<0.001
  \<1 y                                                  819       107.9   (100.5--115.3)   \<0.001        
  1--4 y                                                 469       201.4   (183.2--219.6)   \<0.001        
  5--9 y                                                 117       118.5   (97.1--140.0)    \<0.001        
  10--14 y                                               104       84.7    (68.4--101.0)    \<0.001        
  15--19 y                                               118       50.9    (41.7--60.1)     \<0.001        
  20--24 y                                               70        32.4    (24.8--40.0)     \<0.001        
  25--34 y                                               58        7.58    (5.63--9.53)     \<0.001        
  Mild CHD                                               97        17.6    (14.1--21.1)     \<0.001        
  Moderate CHD                                           360       56.3    (50.5--62.1)     \<0.001        
  Severe 2V CHD                                          465       157.1   (142.8--171.4)   \<0.001        
  Severe 1V CHD                                          673       501.9   (463.9--539.8)   \<0.001        
  Females                                                748       85.3    (79.2--91.3)     \<0.001        
  Males                                                  1017      58.7    (55.1--62.4)     \<0.001        
  Early Era[b](#jah33669-note-0005){ref-type="fn"}       632       167.6   (154.5--180.7)   \<0.001        
  Mid Era[b](#jah33669-note-0005){ref-type="fn"}         506       101.6   (92.8--110.5)    \<0.001        
  Late Era[b](#jah33669-note-0005){ref-type="fn"}        475       81.3    (74.0--88.6)     \<0.001        
  Other congenital malformations                         Overall   118     7.00             (5.74--8.27)   \<0.001
  \<1 y                                                  46        3.83    (2.73--4.94)     \<0.001        
  1--4 y                                                 36        20.5    (13.8--27.2)     \<0.001        
  5--9 y                                                 8         9.42    (2.89--15.9)     0.012          
  10--14 y                                               5         7.28    (0.90--13.7)     0.054          
  15--19 y                                               8         14.1    (4.32--23.8)     0.009          
  20--24 y                                               7         17.9    (4.63--31.1)     0.013          
  25--34 y                                               8         15.2    (4.66--25.7)     0.008          
  Mild CHD                                               27        7.38    (4.60--10.2)     \<0.001        
  Moderate CHD                                           38        6.76    (4.61--8.91)     \<0.001        
  Severe 2V CHD                                          20        4.68    (2.63--6.73)     \<0.001        
  Severe 1V CHD                                          21        9.96    (5.70--14.2)     \<0.001        
  Females                                                48        6.78    (4.86--8.69)     \<0.001        
  Males                                                  70        7.17    (5.49--8.85)     \<0.001        
  Early Era[b](#jah33669-note-0005){ref-type="fn"}       31        6.60    (4.28--8.24)     \<0.001        
  Mid Era[b](#jah33669-note-0005){ref-type="fn"}         43        8.45    (5.94--11.00)    \<0.001        
  Late Era[b](#jah33669-note-0005){ref-type="fn"}        29        4.81    (3.06--6.56)     \<0.001        
  Respiratory diseases                                   Overall   92      8.24             (6.55--9.92)   \<0.001
  \<1 y                                                  27        10.9    (6.78--15.0)     \<0.001        
  1--4 y                                                 25        14.8    (9.02--20.6)     \<0.001        
  5--9 y                                                 8         8.50    (2.61--14.39)    0.013          
  10--y                                                  6         5.51    (1.10--9.92)     0.045          
  15--19 y                                               7         6.71    (1.74--11.68)    0.024          
  20--24 y                                               10        9.70    (3.69--15.72)    0.005          
  25--34 y                                               8         3.50    (1.07--5.92)     0.043          
  Mild CHD                                               22        5.96    (3.47--8.45)     \<0.001        
  Moderate CHD                                           23        5.96    (3.52--8.39)     \<0.001        
  Severe 2V CHD                                          24        14.3    (8.55--19.9)     \<0.001        
  Severe 1V CHD                                          14        18.7    (8.90--28.5)     \<0.001        
  Females                                                40        8.77    (6.05--11.49)    \<0.001        
  Males                                                  52        7.87    (5.73--10.01)    \<0.001        
  Early Era[b](#jah33669-note-0005){ref-type="fn"}       26        10.5    (6.48--14.6)     \<0.001        
  Mid Era[b](#jah33669-note-0005){ref-type="fn"}         19        7.49    (4.12--10.86)    \<0.001        
  Late Era[b](#jah33669-note-0005){ref-type="fn"}        29        11.0    (7.00--15.0)     \<0.001        
  Infections                                             Overall   85      8.16             (6.42--9.89)   \<0.001
  \<1 y                                                  27        14.1    (8.76--19.4)     \<0.001        
  1--4 y                                                 28        18.8    (11.9--25.8)     \<0.001        
  5--9 y                                                 1         1.36    (0--4.01)        0.793          
  10--14 y                                               8         13.7    (4.21--23.2)     0.009          
  15--19 y                                               11        16.5    (6.75--26.3)     0.002          
  20--24 y                                               5         5.40    (0.67--10.1)     0.068          
  25--34 y                                               2         0.61    (0--1.46)        0.373          
  Mild CHD                                               12        3.38    (1.47--5.29)     0.015          
  Moderate CHD                                           20        5.51    (3.15--8.07)     \<0.001        
  Severe 2V CHD                                          22        16.5    (9.57--23.3)     \<0.001        
  Severe 1V CHD                                          24        41.2    (24.7--57.7)     \<0.001        
  Females                                                41        9.86    (6.84--12.87)    \<0.001        
  Males                                                  44        7.03    (4.95--9.10)     \<0.001        
  Early Era[b](#jah33669-note-0005){ref-type="fn"}       18        7.43    (4.00--10.9)     \<0.001        
  Mid Era[b](#jah33669-note-0005){ref-type="fn"}         29        13.1    (8.30--17.8)     \<0.001        
  Late Era[b](#jah33669-note-0005){ref-type="fn"}        23        12.3    (7.24--17.3)     \<0.001        
  Neoplasms                                              Overall   53      1.91             (1.39--2.43)   \<0.001
  \<1 y                                                  1         2.51    (0--7.44)        0.547          
  1--4 y                                                 9         3.54    (1.23--5.87)     0.031          
  5--9 y                                                 7         1.99    (0.52--3.47)     0.188          
  10--14 y                                               8         2.43    (0.75--4.11)     0.096          
  15--19 y                                               10        2.85    (1.08--4.61)     0.040          
  20--24 y                                               7         2.27    (0.59--3.94)     0.140          
  25--34 y                                               8         0.98    (0.30--1.66)     0.949          
  Mild CHD                                               18        1.66    (0.89--2.43)     0.092          
  Moderate CHD                                           16        1.67    (0.85--2.49)     0.109          
  Severe 2V CHD[c](#jah33669-note-0006){ref-type="fn"}   10        3.78    (1.44--6.12)     0.020          
  Severe 1V CHD[c](#jah33669-note-0006){ref-type="fn"}   3         2.82    (0--6.01)        0.264          
  Females                                                23        1.82    (1.08--2.57)     0.030          
  Males                                                  30        1.99    (1.23--2.70)     \<0.001        
  Early Era[b](#jah33669-note-0005){ref-type="fn"}       12        2.57    (1.11--4.00)     0.035          
  Mid Era[b](#jah33669-note-0005){ref-type="fn"}         12        2.39    (1.04--3.75)     0.044          
  Late Era[b](#jah33669-note-0005){ref-type="fn"}        13        2.56    (1.18--3.98)     0.027          
  External causes                                        Overall   207     1.08             (0.93--1.23)   0.293
  \<1 y                                                  17        4.75    (2.49--7.01)     0.001          
  1-- 4 y                                                22        1.72    (1.00--2.44)     0.049          
  5-- 9 y                                                30        3.28    (2.10--4.44)     \<0.001        
  10--14 y                                               16        1.38    (0.70--2.05)     0.272          
  15--19 y                                               44        0.96    (0.68--1.25)     0.792          
  20--24 y                                               42        0.95    (0.66--1.23)     0.708          
  25--34 y                                               32        0.55    (0.36--0.74)     \<0.001        
  Mild CHD                                               70        1.00    (0.76--1.23)     0.978          
  Moderate CHD                                           68        0.98    (0.75--1.21)     0.869          
  Severe 2V CHD                                          25        1.34    (0.82--1.87)     0.201          
  Severe 1V CHD                                          16        2.38    (1.22--3.55)     0.020          
  Females                                                40        1.05    (0.76--1.36)     0.759          
  Males                                                  157       1.09    (0.91--1.26)     0.301          
  Early Era[b](#jah33669-note-0005){ref-type="fn"}       55        1.78    (1.31--2.25)     0.001          
  Mid Era[b](#jah33669-note-0005){ref-type="fn"}         39        1.22    (0.84--1.61)     0.253          
  Late Era[b](#jah33669-note-0005){ref-type="fn"}        43        1.46    (1.03--1.90)     0.039          
  Other medical causes                                   Overall   207     2.06             (1.76--2.34)   \<0.001
  \<1 y                                                  57        0.98    (0.73--1.24)     0.907          
  1--4 y                                                 44        7.62    (5.37--9.87)     \<0.001        
  5--9 y                                                 18        5.21    (2.80--7.61)     \<0.001        
  10--14 y                                               19        4.79    (2.64--6.95)     \<0.001        
  15--19 y                                               25        4.48    (2.72--6.24)     \<0.001        
  20--24 y                                               24        3.85    (2.31--5.38)     \<0.001        
  25--34 y                                               20        1.41    (0.78--2.03)     0.192          
  Mild CHD                                               61        2.38    (1.78--2.96)     \<0.001        
  Moderate CHD                                           59        1.75    (1.30--2.20)     0.001          
  Severe 2V CHD                                          27        1.25    (0.78--1.72)     \<0.001        
  Severe 1V CHD                                          35        3.36    (2.25--4.47)     \<0.001        
  Females                                                80        2.05    (1.60--2.50)     \<0.001        
  Males                                                  127       2.06    (1.70--2.42)     \<0.001        
  Early Era[b](#jah33669-note-0005){ref-type="fn"}       53        2.20    (1.60--2.79)     \<0.001        
  Mid Era[b](#jah33669-note-0005){ref-type="fn"}         60        2.41    (1.80--3.02)     \<0.001        
  Late Era[b](#jah33669-note-0005){ref-type="fn"}        52        1.71    (1.25--2.18)     0.003          

1V indicates 1 ventricle; 2V, 2 ventricles; CHD, congenital heart defects; CI, confidence interval; CVD, cardiovascular disorder; SMR, standardized mortality ratio.

Overall SMR and SMRs by era and CHD severity are adjusted for sex, year of death, and age at death. SMRs by sex are adjusted for age at death and year of death. SMRs by age strata are adjusted for year of death and sex.

Deaths occurring after 15 years of follow‐up were not included in the SMR calculations for era. This truncation was necessary for making follow‐up time comparable among eras. As a result, death counts across eras do not sum to total death count for a specific cause.

Combined SMR for severe CHD: 3.50 (95% CI: 1.6--5.51) (*P*=0.001).

Significantly increased SMRs were also noted for other COD such as associated congenital malformations (SMR 7.0; 95% CI: 5.74--8.27), respiratory diseases (SMR 8.24; 95% CI: 6.55--9.92), infections (SMR 8.16; 95% CI: 6.42--9.89), and neoplasms (SMR 1.91; 95% CI: 1.39--2.43) (Table [2](#jah33669-tbl-0002){ref-type="table"}). Additionally, there were age‐specific differences in risk of death caused by neoplasms and external causes. The higher risk from neoplasms affected only ages 1 to 4 years and 15 to 19 years, most notably in the group with severe CHD. Finally, risk of death from external causes did not differ overall from the general population, but it was increased for ages \<10 years and decreased for ages 25 to 34 years. In a sensitivity analysis excluding patients with an ICD code referring to events associated with surgical care (some of which may refer to operations for CHD), the differential risk persisted for those aged 5 to 9 years and 25 to 34 years (Table [S10](#jah33669-sup-0001){ref-type="supplementary-material"}). Of interest, the proportion of deaths from motor vehicle accidents was higher, while the proportion for homicide/assaults was lower, for CHD patients \>20 years of age compared with the general population (Table [S11](#jah33669-sup-0001){ref-type="supplementary-material"}).

Comparison of Causes of Death by Patient Characteristics {#jah33669-sec-0020}
--------------------------------------------------------

The risk of death caused by CHD/CVD was higher in women (SMR in females 85.3; 95% CI: 79.2--91.3 versus men 58.7; 95% CI: 55.1--62.4) (Table [2](#jah33669-tbl-0002){ref-type="table"}). Adjusted odds ratios between females and males revealed increased odds of death from a CHD or CVD in females \[odds ratio=1.28; 95% CI (1.04--1.58); *P*=0.018\]. Women had higher percentage of deaths caused by contribution from pulmonary heart disease, while men were more prone to arrhythmias, but after adjustment for severity none of these reached significance (Table [S5](#jah33669-sup-0001){ref-type="supplementary-material"}). Stratified analysis by age did not reveal any significant difference between females and males during the reproductive age between 20 and 34 years of age. In addition, there were only 3 events coded as deaths associated with pregnancy, childbirth, and the puerperium.

Adjusted odds ratios for COD by race demonstrated that blacks had mild decrease in the odds of deaths from neoplasms relative to whites, but increased odds of death from "other" causes. There was no difference in the percentage of the various contributing causes of death between whites and blacks (Table [S12](#jah33669-sup-0001){ref-type="supplementary-material"}).

Most deaths in patients with moderate and severe CHD were associated with CHD/CVD (57.5% for moderate, 79.6% for severe two‐ventricle, and 88.9% for SV) (Figure [3](#jah33669-fig-0003){ref-type="fig"}A and Table [S13](#jah33669-sup-0001){ref-type="supplementary-material"}). For patients with mild CHD, 47.5% of death records included CHD or CVD among the multiple causes of death. Patent ductus arteriosus was the condition with the lowest frequency of CHD/CVD--associated deaths. Frequently reported CVDs as multiple COD included heart failure, cardiac arrest, and arrhythmias, but with considerable variation across the spectrum of CHD (Table [S14](#jah33669-sup-0001){ref-type="supplementary-material"}). The in‐depth analysis of the multiple COD is outside of the scope of this report.

An era effect was observed on the CHD/CVD--related risk of death with progressive decline over time across all categories of CHD. This decline was driven mostly by decreases in CHD‐related mortality, while CVD‐related risk of death remained relatively constant over time (Table [S15](#jah33669-sup-0001){ref-type="supplementary-material"}).

Discussion {#jah33669-sec-0021}
==========

Risk of Death From CHD and Cardiovascular Causes of Death {#jah33669-sec-0022}
---------------------------------------------------------

Our data show the majority of premature mortality in patients surviving to hospital discharge after CHS is CHD related and occurs before 5 years of age (Figure [S1](#jah33669-sup-0001){ref-type="supplementary-material"}) with a gradual decline as the follow‐up time increases after the first operation. Much of this may reflect perioperative mortality following subsequent procedures, as patients undergoing staged surgical strategies are often reoperated within this age range.

Mortality from cardiovascular conditions not directly linked to the underlying CHD was the next most frequent cause of death, and was higher than the general population across all severity groups, even for mild forms of CHD. The excess risk for CHD/CVD mortality persisted throughout the follow‐up period, but gradually decreased over time.

Among the CVD conditions contributing to death, heart failure, arrhythmias, and conduction abnormalities were most frequent, highlighting the significant residual cardiovascular morbidity. Pulmonary heart disease, cerebrovascular conditions, and myocardial ischemia were less frequently reported. Over time after CHS, there was a shift from CHD and cardiac arrests towards more heart failure and arrhythmia‐related deaths. As expected, there was considerable variation in the underlying and contributing COD between individual lesions, reflecting the differences in their underlying physiology, severity, and residual abnormalities. The detailed analysis of this variation is outside the scope of this report.

The higher risk of death from CHD in females after discharge parallels our observations of in‐hospital deaths after CHS.[36](#jah33669-bib-0036){ref-type="ref"} A potential cause for that differential risk of death caused by CHD may be pregnancy‐related events; however, the available number of events could not confirm this hypothesis. There were no sex differences for CVD‐related deaths besides a trend towards more pulmonary heart disease--related deaths in females consistent with their reported higher incidence of pulmonary hypertension.[37](#jah33669-bib-0037){ref-type="ref"}

Non‐CHD/Non‐CVD Causes of Death {#jah33669-sec-0023}
-------------------------------

In contrast to the CHD/CVD causes, risk of death from noncardiovascular causes generally increased with age. Among these causes, excess risk above the general population was noted for respiratory and infectious conditions. This is not surprising given the close relationship between cardiovascular and respiratory health, as well the increased vulnerability of these patients to infectious processes.[38](#jah33669-bib-0038){ref-type="ref"}, [39](#jah33669-bib-0039){ref-type="ref"}, [40](#jah33669-bib-0040){ref-type="ref"} Similarly, the increased risk of death from neoplastic processes in patients with operated CHD has been observed before.[19](#jah33669-bib-0019){ref-type="ref"}, [38](#jah33669-bib-0038){ref-type="ref"} However, the large number of patients in our cohort allowed us to demonstrate an age‐dependent risk of death from neoplasms and identify groups at highest risk. This excess risk may reflect increased incidence of certain forms of cancer, or increased vulnerability to complications of cancer treatment, or both.[41](#jah33669-bib-0041){ref-type="ref"}, [42](#jah33669-bib-0042){ref-type="ref"}, [43](#jah33669-bib-0043){ref-type="ref"}

Risk of death from coexisting congenital anomalies was consistently increased across all age groups and likely reflects the high incidence of such extracardiac abnormalities in this group of patients.[44](#jah33669-bib-0044){ref-type="ref"}

Interestingly, an age‐dependent differential risk was noted for external causes of death. Not previously described, the higher risk from external causes in the group of 5 to 9 years of age suggests increased vulnerability to injuries and accidents during young childhood, when little control can be successfully applied over such exposures. On the other hand, the risk from external causes is moderated in the 25 to 34 years of age group, possibly because of activity restrictions, self‐imposed limitations, decreased involvement in risky behaviors, or self‐selection of a less‐at‐risk subgroup. Suicidal risk was elevated in an adult cohort with tetralogy of Fallot in Taiwan,[26](#jah33669-bib-0026){ref-type="ref"} but was not a substantial source of death in our cohort.

Trends in Modality of Death {#jah33669-sec-0024}
---------------------------

Comparing eras in this cohort demonstrates a promising trend towards decreasing CHD mortality. On the other hand, the persistently elevated CVD‐related risk in each era and across all severity forms of CHD suggests that postoperative cardiovascular sequelae continue to impose a significant burden despite improvements in treating CHD. Moreover, the excess mortality from other causes remained unchanged over time, suggesting limited progress in the management or prevention of these additional non‐CHD morbidities.

Comparison With Other Studies {#jah33669-sec-0025}
-----------------------------

Our findings are similar to those from the population‐based study in Finland,[8](#jah33669-bib-0008){ref-type="ref"} the only other large study of modes of death among patients with operated CHD. This study included about 11 000 patients and spanned over 60 years; however, most of these patients had lesions of mild or uncharacterized severity, and only a few of them have complex or single‐ventricle forms of CHD. In contrast to the Finnish study, we found the effect of era on CHD‐related mortality was seen across most CHD lesions and not just ventricular septal defect, perhaps related to the larger sample size or ability to distinguish CHD‐ versus CVD‐related deaths in our cohort.

Other studies on this subject are not directly comparable to the PCCC and Finnish studies because they include a mixed population of adult‐only patients with operated and unoperated CHD.[7](#jah33669-bib-0007){ref-type="ref"}, [9](#jah33669-bib-0009){ref-type="ref"}, [12](#jah33669-bib-0012){ref-type="ref"}, [34](#jah33669-bib-0034){ref-type="ref"}, [45](#jah33669-bib-0045){ref-type="ref"}, [46](#jah33669-bib-0046){ref-type="ref"}, [47](#jah33669-bib-0047){ref-type="ref"}, [48](#jah33669-bib-0048){ref-type="ref"} However, despite these methodological differences, the overall distribution of COD was very similar, at least for the lesions with sufficient numbers of patients.

Limitations {#jah33669-sec-0026}
-----------

Limitations of this study are those inherent to its registry‐based, retrospective nature. As a result, the number of eligible patients who survive to discharge by era may reflect the number and size of centers contributing data to the registry during the different era as well as the increased number of patients operated and surviving operations over time. In addition, information regarding subsequent procedures, residual defects, socioeconomic data, and lifestyle exposures is limited.

An additional limitation is the quality of COD codes available in the NDI‐*Plus*; few deaths in our cohort fell in the unknown category, so this is unlikely to significantly affect the findings of our study, but there are other known limitations of this resource including risk for misclassification of chronic conditions, attribution errors, and use of mode instead of actual COD.[49](#jah33669-bib-0049){ref-type="ref"} Nevertheless, the NDI has been used extensively to understand COD across a wide range of conditions and has been generally found to provide meaningful results.[50](#jah33669-bib-0050){ref-type="ref"} Of importance for our study comparing COD between different pathophysiologies, there is no reason to believe that misattribution of COD would have been differential by lesion.

Despite these limitations, the concordance of our findings with similar studies supports the validity of the methodology used. As the PCCC contains a much larger number of patients than previously reported studies, the data suggest that our approach can be used with confidence to understand the specific risks associated with even the rarest CHD for which other cohorts contain very few events or no data at all.

Operative techniques and medical care continue to evolve; thus, long‐term outcomes and cause‐specific risks are expected to change over time. Experience has shown that apart from conditions with radical changes in their management, treatment for many conditions evolves gradually without major shifts in risk. Continuous monitoring of our cohort will allow us to identify major risks in survivors with operated CHD and focus on strategies that will reduce their hazards.

Conclusions {#jah33669-sec-0027}
===========

Survivors of CHS face long‐term risks for premature mortality, with deaths attributed most often to residual CHD pathology, heart failure, and arrhythmias, but also to other noncardiac conditions. As a result, ongoing monitoring of this population is warranted and additional research is needed to identify modifiable factors that can be targeted to address residual morbidities and improve long‐term outcomes.

Sources of Funding {#jah33669-sec-0029}
==================

This study was supported by National Heart, Lung, and Blood Institute R01 HL122392 and NIH CTSA Award UL1TR000114.

Disclosures {#jah33669-sec-0030}
===========

None.

Supporting information
======================

###### 

**Data S1.** Supplemental Methods.

**Table S1.** ICD‐9 and ICD‐10 Codes Associated with Cause of Death Groupings

**Table S2.** Breakdown of "Other" Underlying Causes of Death

**Table S3.** Underlying Cause of Death by Age‐Sex Stratification

**Table S4.** Underlying Cause of Death by Time Since Initial Congenital Heart Surgery

**Table S5.** Frequency of CHD and CVD Codes as Contributing Causes of Death

**Table S6.** Summary Statistics for Multiple Causes of Death\*

**Table S7.** Underlying Cause of Death in Patients With Non‐CHD/non‐CVD‐Associated Death

**Table S8.** SMRs for Congenital Heart Defects (CHD) or Cardiovascular Disorders (CVD)

**Table S9.** SMR for Underlying Causes of Death by Major Physiology Group

**Table S10.** SMR for External Causes of Death Excluding Surgical Misadventures

**Table S11.** List of External Causes of Death by Age Group and Estimates from Age‐Matched US Population of Deaths by External Causes from 1981 to 2014

**Table S12.** Distribution of Underlying and Multiple Causes of Death by Race

**Table S13.** Modes of Death by CHD Group

**Table S14.** Underlying and Contributing Causes of Death by CHD Group

**Table S15.** Era Effect on the SMR for CVD/CHD‐Associated Death by Physiology Group

**Figure S1.** Distribution of cumulative causes of death after the first congenital heart surgery (CHS).

###### 

Click here for additional data file.

We thank the program directors and data collection coordinators from the participating Pediatric Cardiac Care Consortium (PCCC) centers; without their effort and dedication, this work could not have been completed. Susan Anderson and Brian Harvey were especially instrumental in the management of PCCC and initial linkage of this cohort with mortality information.
